EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Statins in Chronic Liver Disease: Review of the Literature and Future Role

Nguyen Pham, Jihane N Benhammou

Seminars in Liver Disease · 2024-05 · 44 (02) · 191-208

DOI: 10.1055/a-2319-0694 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, online erschienen am 29.05.2024. Verfasst von Nguyen Pham und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, Los Angeles, Los Angeles, California. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 235 Literaturangaben. Gefördert von: CSRD VA, VA Greater Los Angeles Healthcare System.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic liver disease (CLD) is a major contributor to global mortality, morbidity, and healthcare burden. Progress in pharmacotherapeutic for CLD management is lagging given its impact on the global population. While statins are indicated for the management of dyslipidemia and cardiovascular disease, their role in CLD prevention and treatment is emerging. Beyond their lipid-lowering effects, their liver-related mechanisms of action are multifactorial and include anti-inflammatory, antiproliferative, and immune-protective effects. In this review, we highlight what is known about the clinical benefits of statins in viral and nonviral etiologies of CLD and hepatocellular carcinoma (HCC), and explore key mechanisms and pathways targeted by statins. While their benefits may span the spectrum of CLD and potentially HCC treatment, their role in CLD chemoprevention is likely to have the largest impact. As emerging data suggest that genetic variants may impact their benefits, the role of statins in precision hepatology will need to be further explored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsHumansChronic DiseaseLiver NeoplasmsCarcinoma, HepatocellularLiver DiseasesAnimalsTreatment Outcome

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Veterans Affairs Greater Los Angeles, Los Angeles, California.
  • Comprehensive Liver Research Center at University of California, Los Angeles, Los Angeles, California.

Förderung

  • CSRD VA
  • VA Greater Los Angeles Healthcare System

Zitieren

APA

Pham, N., & Benhammou, J. N. (2024). Statins in Chronic Liver Disease: Review of the Literature and Future Role. Seminars in Liver Disease, 44(02), 191-208. https://doi.org/10.1055/a-2319-0694

Vancouver

Pham N, Benhammou JN. Statins in Chronic Liver Disease: Review of the Literature and Future Role. Seminars in Liver Disease. 2024;44(02):191-208. doi:10.1055/a-2319-0694

BibTeX
@article{Pham2024,
  author = {Pham, Nguyen and Benhammou, Jihane N},
  title = {Statins in Chronic Liver Disease: Review of the Literature and Future Role},
  journal = {Seminars in Liver Disease},
  year = {2024},
  volume = {44},
  number = {02},
  pages = {191--208},
  doi = {10.1055/a-2319-0694}
}
Kostenlos starten →